R. Lor Randall
2.3K posts
@RLRandallMD
I am so fortunate to serve as Chair of the storied Department of Orthopaedic Surgery at the University of California, Davis. Tweets are my own.
.@RLRandallMD, highlights a recent meta-analysis comparing 2 approaches to surgical management for patients with femoral metastases. @UCD_Cancer #scmsm #oncology onclive.com/view/im-nailin…
⚛️ “This consensus provides much-needed initial clarity for the day-to-day management of PJIs in patients [with sarcoma] but also underscores how much work remains to elevate the evidence base,” said @RLRandallMD of @ucdavis on key takeaways from the BOOM consensus meeting on PJI management in orthopedic oncology. Read more here 📈: hubs.li/Q049NCYq0 #oncology
How should periprosthetic joint infections be managed in orthopedic oncology when high-level evidence is limited? In this clip, @RLRandallMD of @UCD_Cancer discusses the clinical impetus for the Birmingham Orthopedic Oncology Meeting (BOOM) initiative and the rationale for using a modified Delphi consensus approach in the setting of limited high-level evidence. ▶️ Watch this short and read the full Q&A for key takeaways from the BOOM report:🔗 hubs.li/Q048GXl20 #BoomConsensus #BOOM2026 #BJJ #orthopediconcology
WATCH 📺: @RLRandallMD of @UCDavisHealth outlines key clinical and treatment variables associated with local recurrence risk in patients with nonmetastatic Ewing sarcoma treated with interval compression therapy. 📊 Delve into findings from this contemporary analysis by watching the video below! 👇 #sarcsm #oncology onclive.com/view/dr-randal…
👀“The take-home message in this modern multi-modality therapy study is that future efforts should focus on identifying and intensifying treatment for the high-risk subsets," said @RLRandallMD of @UCD_Cancer on a local therapy modality analysis in nonmetastatic ewing sarcoma. Read more here ➡️: hubs.li/Q044LW4p0 #oncology
Diffuse #TGCT remains a challenge, but targeted therapies offer new hope. Discover expert strategies for integrating CSF1R inhibitors into personalized care plans. Drs. @WTapMD & @RLRandallMD discuss clinical data and patient cases at #CTOS2025 #MedEd 📺 Participate now: bit.ly/3IpZHxa
🌎 "Standardization is essential. Without unified definitions, multicenter trials and meta-analyses are impossible," said @RLRandallMD of @UCD_Cancer, on the need for standard DAIR terminology. Read more here 📰: hubs.li/Q03-dZ390 #oncology
"These findings reinforce the disconnect between preclinical promise and clinical efficacy in this disease" said @RLRandallMD of @UCDavisHealth on safety and efficacy data for denosumab in AYA osteosarcoma. 👀 Read more here 📰: hubs.li/Q03YRF6r0 #scmsm #oncology
Join us for a deep dive into #TGCT pathogenesis, clinical evidence, and real-world case discussions from the #CTOS2025 symposium! Drs. @WTapMD & @RLRandallMD share strategies and practical approaches to managing this rare disease #MedEd #oncology 🔗 bit.ly/3IpZHxa
Denosumab Displays Tolerability, Combination Potential in AYA Osteosarcoma @RLRandallMD @UCD_Cancer #oncology #sarcoma hubs.li/Q03YnYNB0
